Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone and vascular response to norepinephrine in septic shock
2020-001430-35Phase 3Terminated
- Sponsor
- CHU Rennes
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fludrocortisone in septic shock, sponsored by CHU Rennes. Primary endpoint: Vascular reactivity to norepinephrine (primary). Started Feb 2021; status: terminated.
02
Drugs
fludrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on 2020-001430-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001430-35.